Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer

Oliver J Pickles, Aneta Drozd, Louise Tee, Andrew D Beggs, Gary W Middleton

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences